Yahoo Finance A Look at Sarepta Therapeutics’ Recent Developments
Who Is Eyeing Sarepta Therapeutics Now? (Continued from Prior Part) ## Earnings trends In the first nine months of 2018, Sarepta Therapeutics’ (SRPT) net income and EPS amounted to -$221.0 million and -$3.38, respectively, compared to -$26.7 million and -$0.47 in the same period the prior year. In the third quarter of 2018, the company reported net income and EPS of -$76.4 million and -$1.15, respectively, compared to -$47.7 million and -$0.78 in the third quarter of 2017. Wall Street analysts anticipate that in the fourth quarter of 2018, Sarepta Therapeutics will report net income and EPS of -$63.26 million and -$0.95, respectively. Analysts also estimate that the company will report net income and EPS of -$274.73 million and -$4.16, respectively, in fiscal 2018. Wall Street analysts estimate that BioMarin Pharmaceuticals (BMRN), Nektar Therapeutics (NKTR), and Vertex Pharmaceuticals (VRTX), Sarepta Therapeutics’ peers in the biopharmaceuticals market, will report EPS of around -$0.62, $3.88, and $2.88, respectively, in fiscal 2018. ## Recent developments On January 2, 2019, Sarepta Therapeutics entered a long-term strategic relationship with Aldevron. Aldevron is one of the leading producers of custom proteins, nucleic acids, and antibodies for use in the biotech industry. As per the terms of the agreement, Aldevron will supply plasmid DNA for the fulfillment of Sarepta Therapeutics’ requirements in its gene therapy clinical trials and commercial purposes. Aldevron will specifically supply GMP-grade plasmid for Sarepta Therapeutics’ micro-dystrophin Duchenne muscular dystrophy (or DMD) and Limb-girdle muscular dystrophy (or LGMD) gene therapy programs. As per the terms of the agreement, Aldevron will also supply plasmid for Sarepta Therapeutics’ future gene therapy programs. The agreement is expected to help Sarepta Therapeutics with sufficient plasmid for research and commercial purposes. Browse this series on Market Realist: * Part 1 - Sarepta Therapeutics Stock Rose 96% in 2018 * Part 2 - How Is Sarepta Therapeutics Positioned in January?
